Trial reportNature2020
Clinical targeting of HIV capsid protein with a long-acting small molecule.
Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph
Trial report in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03739866 (A Phase 1b Randomized, Double-Blinded, Placebo Controlled, Multi-Cohort Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Subjects), which is not on this map. Cited by 255 papers.
0numbers the graph read from it
0cells of the map it votes in
255citing papers in PubMed
25.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1b Randomized, Double-Blinded, Placebo Controlled, Multi-Cohort Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Subjects
Who cites it
255 citing papers in PubMed, 403 citations in OpenAlex.
- Lenacapavir Use in France: A National, Observational Study (LENAddOn).Open forum infectious diseases · 2026Trial
- Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study.AIDS (London, England) · 2026Trial
- Effectiveness and Safety of Lenacapavir-Containing Regimens in Highly Experienced HIV-Infected Patients With Multidrug Resistance: Real-world Results From the French Compassionate Use ProgramOpen forum infectious diseases · 2026Trial
- Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered.AIDS (London, England) · 2025Trial
- Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.The lancet. HIV · 2024Trial
- Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring.British journal of clinical pharmacology · 2026Article
- Mechanisms of HIV-1 assembly, release and maturation.Nature reviews. Microbiology · 2026Review
- Systematic exploration of predicted quaternary structures within pandemic-relevant viral proteomes.bioRxiv : the preprint server for biology · 2026Article
- Review
- Structural basis of lenacapavir-induced HIV-1 capsid defects during virion maturation.Nature communications · 2026Article
- Inhibitors of HIV-1 maturation modulate conformational dynamics and heterogeneity of the immature Gag lattice.bioRxiv : the preprint server for biology · 2026Article
- Lenacapavir binding to immature Gag induces giant virions and causes protease-dependent inhibition of viral release.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Mechanistic Insights into HIV-1 Capsid Interactions with CPSF6.bioRxiv : the preprint server for biology · 2026Article
- Lenacapavir allosterically remodels the HIV-1 capsid.Science advances · 2026Article
- HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy.The Journal of antimicrobial chemotherapy · 2026Article
- Article
- Mis-localized nucleoporin POM121C potently inhibits nuclear entry of HIV-1 but leads to the outgrowth of viral escape mutants.Journal of virology · 2026Article
- Siglec-1-targeted nanobodies restrict HIV-1 transmission and infection of dendritic cells.Journal of virology · 2026Article
- Review
- Capsid stabilization reprograms the nuclear fate of the HIV genome.Science advances · 2026Article
195 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
73 authors at 8 institutions in 1 country.
John O LinkGilead Sciences, Foster City, CA, USA.
Martin S RheeGilead Sciences, Foster City, CA, USA.
Winston C TseGilead Sciences, Foster City, CA, USA.
Jim ZhengGilead Sciences, Foster City, CA, USA.
John R SomozaGilead Sciences, Foster City, CA, USA.
William RoweGilead Sciences, Foster City, CA, USA.
Rebecca BegleyGilead Sciences, Foster City, CA, USA.
Anna ChiuGilead Sciences, Foster City, CA, USA.
Andrew MulatoGilead Sciences, Foster City, CA, USA.
Derek HansenGilead Sciences, Foster City, CA, USA.
Eric SingerGilead Sciences, Foster City, CA, USA.
Luong K TsaiGilead Sciences, Foster City, CA, USA.
Rujuta A BamGilead Sciences, Foster City, CA, USA.
Chien-Hung ChouGilead Sciences, Foster City, CA, USA.
Eda CanalesGilead Sciences, Foster City, CA, USA.
Gediminas BrizgysGilead Sciences, Foster City, CA, USA.
Jennifer R ZhangGilead Sciences, Foster City, CA, USA.
Jiayao LiGilead Sciences, Foster City, CA, USA.
Michael GraupeGilead Sciences, Foster City, CA, USA.
Philip MorganelliGilead Sciences, Foster City, CA, USA.
Qi LiuGilead Sciences, Foster City, CA, USA.
Qiaoyin WuGilead Sciences, Foster City, CA, USA.
Randall L HalcombGilead Sciences, Foster City, CA, USA.
Roland D SaitoGilead Sciences, Foster City, CA, USA.
Scott D SchroederGilead Sciences, Foster City, CA, USA.
Scott E LazerwithGilead Sciences, Foster City, CA, USA.
Steven BondyGilead Sciences, Foster City, CA, USA.
Debi JinGilead Sciences, Foster City, CA, USA.
Magdeleine HungGilead Sciences, Foster City, CA, USA.
Nikolai NovikovGilead Sciences, Foster City, CA, USA.
Xiaohong LiuGilead Sciences, Foster City, CA, USA.
Armando G VillaseñorGilead Sciences, Foster City, CA, USA.
Carina E CannizzaroGilead Sciences, Foster City, CA, USA.
Eric Y HuGilead Sciences, Foster City, CA, USA.
Robert L AndersonGilead Sciences, Foster City, CA, USA.
Todd C ApplebyGilead Sciences, Foster City, CA, USA.
Bing LuGilead Sciences, Foster City, CA, USA.
Judy MwangiGilead Sciences, Foster City, CA, USA.
Albert LiclicanGilead Sciences, Foster City, CA, USA.
Anita Niedziela-MajkaGilead Sciences, Foster City, CA, USA.
Giuseppe A PapaliaGilead Sciences, Foster City, CA, USA.
Melanie H WongGilead Sciences, Foster City, CA, USA.
Stephanie A LeavittGilead Sciences, Foster City, CA, USA.
Yili XuGilead Sciences, Foster City, CA, USA.
David KoditekGilead Sciences, Foster City, CA, USA.
George J StepanGilead Sciences, Foster City, CA, USA.
Helen YuGilead Sciences, Foster City, CA, USA.
Nikos PagratisGilead Sciences, Foster City, CA, USA.
Sheila ClancyGilead Sciences, Foster City, CA, USA.
Shekeba AhmadyarGilead Sciences, Foster City, CA, USA.
Terrence Z CaiGilead Sciences, Foster City, CA, USA.
Scott SellersGilead Sciences, Foster City, CA, USA.
Scott A WolckenhauerGilead Sciences, Foster City, CA, USA.
John LingGilead Sciences, Foster City, CA, USA.
Christian CallebautGilead Sciences, Foster City, CA, USA.
Nicolas MargotGilead Sciences, Foster City, CA, USA.
Renee R RamGilead Sciences, Foster City, CA, USA.
Ya-Pei LiuGilead Sciences, Foster City, CA, USA.
Rob HylandGilead Sciences, Foster City, CA, USA.
Gary I SinclairAIDS Arms Inc, DBA Prism Health North Texas, Dallas, TX, USA.
Peter J RuaneRuane Clinical Research Group Inc, Los Angeles, CA, USA.
Gordon E CrofootThe Crofoot Research Center Inc, Houston, TX, USA.
Cheryl K McDonaldTexas Centers for Infectious Disease Associates, Fort Worth, TX, USA.
Diana M BrainardGilead Sciences, Foster City, CA, USA.
Latesh LadGilead Sciences, Foster City, CA, USA.
Swami SwaminathanGilead Sciences, Foster City, CA, USA.
Wesley I SundquistDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA.
Roman SakowiczGilead Sciences, Foster City, CA, USA.
Anne E ChesterGilead Sciences, Foster City, CA, USA.
William E LeeGilead Sciences, Foster City, CA, USA.
Eric S DaarDivision of HIV Medicine at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Torrance, CA, USA.
Stephen R YantGilead Sciences, Foster City, CA, USA. stephen.yant@gilead.com.
Tomas CihlarGilead Sciences, Foster City, CA, USA.
Gilead Sciences (United States) · USAIDS Arms · USBayer (United States) · USHarbor–UCLA Medical Center · USRuane Medical · USTexas Center for Infectious Disease · USUniversity of Utah · USVIR Biotechnology (United States) · US
Funding
Virus TransmissionP50AI150464 · NIAID · UNIVERSITY OF UTAH · PI HOPE, THOMAS · 2019 to 2021
$14.9MNIAID NIH HHS P50 AI150464
Abstract
Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis
Indexed as
AdolescentAdultAnti-HIV AgentsCapsid ProteinsCell LineCells, CulturedDrug Resistance, ViralFemaleHIV-1HumansMaleMiddle AgedModels, MolecularVirus ReplicationYoung AdultAnti-HIV AgentsCapsid Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03739866ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.